Lauren M. Lepone

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

Christopher R. Heery, Geraldine O’Sullivan Coyne, Ravi A. Madan et al. · The Lancet Oncology · 2017 · 292 citations · Full text

Medicine, Javelin Solid Tumor, Solid Tumours +6

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells

Caroline Jochéms, Massimo Fantini, Romaine I. Fernando et al. · Oncotarget · 2016 · 140 citations · Full text

T-regulatory Cell, Immunology, Immune Regulation +24

Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

Arun Rajan, Christopher R. Heery, Anish Thomas et al. · Journal for ImmunoTherapy of Cancer · 2019 · 132 citations · Full text

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody

Renee N. Donahue, Lauren M. Lepone, Italia Grenga et al. · Journal for ImmunoTherapy of Cancer · 2017 · 87 citations · Full text

Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines

Benedetto Farsaci, Renee N. Donahue, Michael A. Coplin et al. · Cancer Immunology Research · 2014 · 80 citations · Full text